Biodesix (BDSX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	31.49 mm	31.49 mm	31.49 mm	31.49 mm	31.49 mm	31.49 mm
Cash burn (monthly)	3.60 mm	(no burn)	2.86 mm	2.89 mm	3.56 mm	4.74 mm
Cash used (since last report)	14.50 mm	n/a	11.52 mm	11.64 mm	14.31 mm	19.05 mm
Cash remaining	16.99 mm	n/a	19.97 mm	19.86 mm	17.19 mm	12.44 mm
Runway (months of cash)	4.7	n/a	7.0	6.9	4.8	2.6

Beta Read what these cash burn values mean

Financial data from Biodesix earnings reports.

Institutional ownership, Q3 2024

BDSX institutional ownership history Ownership history

79.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	56	49	+14.3%
Opened positions	14	19	-26.3%
Closed positions	7	15	-53.3%
Increased positions	13	15	-13.3%
Reduced positions	7	8	-12.5%

13F shares	Current	Prev Q	Change
Total value	100.52 bn	72.10 bn	+39.4%
Total shares	115.42 mm	106.57 mm	+8.3%
Total puts	10.10 k	11.50 k	-12.2%
Total calls	2.60 k	500.00	+420.0%
Total put/call ratio	3.9	23.0	-83.1%

Largest owners	Shares	Value	Change
Schuler Jack W	30.79 mm	$48.35 mm	0.0%
Kennedy Lawrence T. Jr	12.27 mm	$19.26 mm	0.0%
Telemark Asset Management	8.28 mm	$14.74 bn	0.0%
BRYN MAWR TRUST	6.10 mm	$10.85 bn	NEW
AIGH Capital Management	5.68 mm	$10.11 bn	-1.7%
Hirschman Orin	5.57 mm	$7.24 mm	0.0%
Farallon Capital Management	4.64 mm	$8.25 bn	+146.9%
Patience John	4.61 mm	$6.46 mm	0.0%
Sio Capital Management	4.34 mm	$7.72 bn	-0.2%
Soleus Capital Management	4.04 mm	$7.19 bn	-33.9%

Largest transactions	Shares	Bought/sold	Change
BRYN MAWR TRUST	6.10 mm	+6.10 mm	NEW
Farallon Capital Management	4.64 mm	+2.76 mm	+146.9%
Soleus Capital Management	4.04 mm	-2.07 mm	-33.9%
Silverarc Capital Management	3.56 mm	+1.75 mm	+96.9%
LMR Partners	0.00	-1.60 mm	EXIT
BlackRock	568.58 k	+568.58 k	NEW
BLK BlackRock	0.00	-415.91 k	EXIT
Heights Capital Management	318.77 k	+318.77 k	NEW
Perkins Capital Management	724.78 k	+310.00 k	+74.7%
Geode Capital Management	804.58 k	+270.72 k	+50.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BDSX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Nov 24	Schuler Jack W	Common Stock	Buy	Acquire P	Yes	No	1.2284	100,000	122.84 k	31,194,935
21 Nov 24	Kennedy Lawrence T. Jr	Common Stock	Buy	Acquire P	Yes	No	1.1589	35,000	40.56 k	10,411,024
20 Nov 24	Schuler Jack W	Common Stock	Buy	Acquire P	Yes	No	1.17	200,000	234.00 k	31,094,935
12 Nov 24	Kieran O'Kane	Common Stock	Sell	Dispose S	No	No	1.4008	224	313.78	97,448
12 Nov 24	Gary Anthony Pestano	Common Stock	Sell	Dispose S	No	No	1.4008	207	289.97	127,027
11 Nov 24	Kieran O'Kane	Common Stock	Sell	Dispose S	No	No	1.3909	238	331.03	97,672
11 Nov 24	Gary Anthony Pestano	Common Stock	Sell	Dispose S	No	No	1.3909	220	306.00	127,234
8 Nov 24	Kieran O'Kane	Common Stock	Option exercise	Acquire M	No	No	0	1,490	0.00	97,910
8 Nov 24	Kieran O'Kane	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,490	0.00	7,447
8 Nov 24	Gary Anthony Pestano	Common Stock	Option exercise	Acquire M	No	No	0	1,378	0.00	127,454

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Biodesix Sees Q4 Revenues Of $20.4M And FY24 Revenues Of $71.3M Vs. $70.73M Estimate

10 Jan 25

Total revenue is estimated to be $20.4 million and $71.3 million for the fourth quarter and fiscal 2024, respectively, an increase of 39% and 45% over the respective prior year comparable periods;Lung

Biodesix Announced A New Post-market Clinical Validation Study Was Published In CHEST Pulmonary Journal That Reaffirms The Performance Of Nodify CDT Blood-based Lung Nodule Test

7 Jan 25

The Nodify CDT test measures levels of seven autoantibodies associated with lung cancer that can be detected in blood samples of patients with indeterminate lung nodules. Prior studies have demonstrated that elevated

Press releases

From Benzinga Pro

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

10 Jan 25

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

7 Jan 25

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was